应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06887 东阳光药
未开盘 10-07 16:08:52
41.100
-0.420
-1.01%
最高
41.520
最低
40.200
成交量
14.24万
今开
41.520
昨收
41.520
日振幅
3.18%
总市值
235.91亿
流通市值
131.11亿
总股本
5.74亿
成交额
580.22万
换手率
0.04%
流通股本
3.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
东阳光药:张寓帅增持,好仓比例升至40.41%
港股披露 · 10-07 17:22
东阳光药:张寓帅增持,好仓比例升至40.41%
东阳光药10月2日回购100,700股,耗资约416.45万港元
公告速递 · 10-02
东阳光药10月2日回购100,700股,耗资约416.45万港元
东阳光药9月股份变动月报表,股本维持稳定
公告速递 · 10-02
东阳光药9月股份变动月报表,股本维持稳定
东阳光药(06887)10月2日斥资416.45万港元回购10.07万股
智通财经 · 10-02
东阳光药(06887)10月2日斥资416.45万港元回购10.07万股
东阳光药2026年中期财报:营收10.75亿元
公告速递 · 09-30
东阳光药2026年中期财报:营收10.75亿元
东阳光药回购12万股股份,涉资约507.90万港元
公告速递 · 09-29
东阳光药回购12万股股份,涉资约507.90万港元
东阳光药:张寓帅增持,好仓比例升至40.35%
港股披露 · 09-29
东阳光药:张寓帅增持,好仓比例升至40.35%
东阳光药9月28日回购1.6万股股份,涉资约63.55万港元
公告速递 · 09-28
东阳光药9月28日回购1.6万股股份,涉资约63.55万港元
东阳光药(06887.HK)9月28日斥资63.55万港元回购1.6万股
智通财经 · 09-28
东阳光药(06887.HK)9月28日斥资63.55万港元回购1.6万股
东阳光药(06887)提交约3892万内资股转H股备案 计划推进“H股全流通”
公告速递 · 09-23
东阳光药(06887)提交约3892万内资股转H股备案 计划推进“H股全流通”
东阳光药(06887)就拟实施H股全流通向中国证监会备案
智通财经 · 09-23
东阳光药(06887)就拟实施H股全流通向中国证监会备案
东阳光药:李文佳增持,好仓比例升至0.27%
港股披露 · 09-16
东阳光药:李文佳增持,好仓比例升至0.27%
东阳光药:蒋均才增持,好仓比例升至0.07%
港股披露 · 09-16
东阳光药:蒋均才增持,好仓比例升至0.07%
东阳光药更新2026年8月股份变动月报表,股本维持稳定
公告速递 · 09-03
东阳光药更新2026年8月股份变动月报表,股本维持稳定
东阳光药(06887)补充披露合伙基金主要条款及土地估值细节
公告速递 · 08-31
东阳光药(06887)补充披露合伙基金主要条款及土地估值细节
东阳光药发布2026年中期业绩:新旧动能切换,创新引擎接棒
格隆汇 · 08-31
东阳光药发布2026年中期业绩:新旧动能切换,创新引擎接棒
东阳光药2026年中期营收10.75亿元
公告速递 · 08-31
东阳光药2026年中期营收10.75亿元
东阳光药(06887)发布中期业绩,收入10.75亿元 计划将强劲的营运现金流投入研发活动
智通财经 · 08-31
东阳光药(06887)发布中期业绩,收入10.75亿元 计划将强劲的营运现金流投入研发活动
东阳光药(06887)发布盈利警告:预计2026年上半年亏损约5.9亿元
公告速递 · 08-24
东阳光药(06887)发布盈利警告:预计2026年上半年亏损约5.9亿元
东阳光药预计上半年亏损 主要因流感疫情缓解
美股速递 · 08-24
东阳光药预计上半年亏损 主要因流感疫情缓解
暂无数据
公司概况
公司名称:
东阳光药
所属市场:
SEHK
上市日期:
--
主营业务:
广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药,亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威(磷酸奥司他韦),用于治疗流行性感冒(特别是甲型及乙型流行性感冒病毒),东卫恩(磷酸依米他韦),用于治疗丙型肝炎,及主要用于治疗敏感细菌引起的感染的仿制药,即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病,包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。
发行价格:
--
{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":41.1,"timestamp":1791360532009,"preClose":41.52,"halted":0,"volume":142354,"delay":0,"changeRate":-0.010115606936416225,"floatShares":319000000,"shares":574000000,"eps":0.55,"marketStatus":"未开盘","change":-0.42,"latestTime":"10-07 16:08:52","open":41.52,"high":41.52,"low":40.2,"amount":5802193,"amplitude":0.031792,"askPrice":41.1,"askSize":1300,"bidPrice":40.86,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.596326247,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":0,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":41.52,"openAndCloseTimeList":[[1791336600000,1791345600000],[1791349200000,1791360000000]],"volumeRatio":0.202824,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887/tweets","defaultTab":"tweets","newsList":[{"id":"1130302569","title":"东阳光药:张寓帅增持,好仓比例升至40.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130302569","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130302569?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:22","pubTimestamp":1791364931,"startTime":"0","endTime":"0","summary":"张寓帅于2026年10月2日因广东东阳光药业股份有限公司回购100,700股库存股份(每股均价41.3557港元,涉资416.45万港元),而被视为拥有该等库存股份权益,好仓增加10.07万股。张寓帅此次增持前持有东阳光药好仓1.30亿股,占比40.38%;增持后持股量为1.30亿股,好仓比例升至40.41%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139195092","title":"东阳光药10月2日回购100,700股,耗资约416.45万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139195092","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139195092?lang=zh_cn&edition=full","pubTime":"2026-10-02 18:41","pubTimestamp":1790937694,"startTime":"0","endTime":"0","summary":"东阳光药于2026年10月2日发布公告称,公司当日在香港联合交易所场内回购普通股合计100,700股,约占本次回购前该公司已发行股份总数318,838,840股的0.032%。最高回购价每股为41.60港元,最低回购价每股为40.48港元,合计付出的价格总额为4,164,516港元。回购完成后,截至2026年10月2日,东阳光药已发行股份数变更为318,738,140股,库藏股数增至2,365,000股,合并计算公司股份总数为321,103,140股。公告显示,东阳光药确认本次股份回购符合香港联合交易所有关上市规则及其他相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药10月2日回购100,700股,耗资约416.45万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127238146","title":"东阳光药9月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127238146","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127238146?lang=zh_cn&edition=full","pubTime":"2026-10-02 18:41","pubTimestamp":1790937680,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年10月2日披露2026年9月股份变动月报表,报告期为2026年9月1日至9月30日。公告显示,公司注册资本维持人民币576,656,047元不变,由321,103,140股H股和255,552,907股内资股构成。公司于2026年9月28日以每股39.72港元回购H股16,000股;于2026年9月29日以每股42.32港元回购H股120,000股。上述回购股份均被列作库存股份且尚未注销。截至2026年9月末,公司已发行股本总数保持不变,仍为576,656,047股。本次公告由董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672177716","title":"东阳光药(06887)10月2日斥资416.45万港元回购10.07万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2672177716","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672177716?lang=zh_cn&edition=full","pubTime":"2026-10-02 18:40","pubTimestamp":1790937618,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,于2026年10月2日,该公司斥资416.45万港元回购10.07万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118878250","title":"东阳光药2026年中期财报:营收10.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118878250","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118878250?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:47","pubTimestamp":1790776028,"startTime":"0","endTime":"0","summary":"东阳光药公布截至2026年6月30日止六个月的中期业绩,报告期内营收10.75亿元,同比下降44.50%。毛利录得5.78亿元,同比下降60.60%,毛利率为53.77%。同期经营活动现金流为-8.93亿元,而上年同期为2,034.4万元。在抗感染药物板块,收入5.82亿元,较上年同期的14.12亿元减少58.80%。慢病治疗药物收入4.64亿元,同比减少1.90%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东阳光药2026年中期财报:营收10.75亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198216687","title":"东阳光药回购12万股股份,涉资约507.90万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198216687","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198216687?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:41","pubTimestamp":1790678510,"startTime":"0","endTime":"0","summary":"东阳光药于2026年9月29日发布翌日披露报表。公告显示,公司于2026年9月29日在香港联交所场内回购股份120,000股,占2026年9月28日现有已发行股份总数318,958,840股的约0.038%。本次回购价格介乎42.28港元至42.36港元之间,合计付出约507.90万港元。本次回购完成后,公司已发行股份总数仍为321,103,140股,未包括库存股份的已发行股份数量变为318,838,840股,库存股份数量增至2,264,300股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药回购12万股股份,涉资约507.90万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131108924","title":"东阳光药:张寓帅增持,好仓比例升至40.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131108924","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131108924?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:32","pubTimestamp":1790674339,"startTime":"0","endTime":"0","summary":"张寓帅于2026年9月28日因广东东阳光药业股份有限公司(东阳光药,06887)在联交所场内以每股均价39.7188港元回购1.60万股库存股份(涉资约63.55万港元),被视为拥有该等库存股份权益,好仓相应增加。该笔权益变动因公司回购库存股产生,不属张寓帅本人主动交易。张寓帅此次增持前持有东阳光药好仓1.30亿股,占比40.34%;增持后持股量为1.30亿股,好仓比例升至40.35%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184714449","title":"东阳光药9月28日回购1.6万股股份,涉资约63.55万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184714449","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184714449?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:01","pubTimestamp":1790593317,"startTime":"0","endTime":"0","summary":"东阳光药于2026年9月28日公告,该公司在香港联交所场内回购16,000股H股,占本次回购前已发行股份的约0.005%。回购价格介乎每股39.4港元至40港元,合计付出价格约63.55万港元。本次回购完成后,公司已发行股份由318,974,840股减少至318,958,840股,库存股份由2,128,300股增至2,144,300股,公司已发行股本总数仍为321,103,140股。根据公告,购回授权于2026年6月18日获得通过,总数为57,597,844股。公司确认本次回购已遵守香港联交所主板上市规则及相关法律法规。该公告由公司董事张英俊签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药9月28日回购1.6万股股份,涉资约63.55万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670062239","title":"东阳光药(06887.HK)9月28日斥资63.55万港元回购1.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670062239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670062239?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:01","pubTimestamp":1790593289,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192905683","title":"东阳光药(06887)提交约3892万内资股转H股备案 计划推进“H股全流通”","url":"https://stock-news.laohu8.com/highlight/detail?id=1192905683","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192905683?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:06","pubTimestamp":1790161609,"startTime":"0","endTime":"0","summary":"2026年9月23日,广东东阳光药业股份有限公司公告称,公司已就38,921,690股内资股转换为H股的事项向中国证监会提交备案申请,占公司公告当日已发行股本总额约6.75%。\\n\\n根据公司章程及适用中国法律,此次“H股全流通”及相关转换上市计划无需召开股东大会批准。\\n\\n公司提醒股东及潜在投资者,H股全流通及其后续转换上市仍需履行中国证监会、联交所及其他境内外监管机构规定的相关程序,买卖公司证券时应保持谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100426","title":"东阳光药(06887)就拟实施H股全流通向中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100426","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669100426?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:04","pubTimestamp":1790161483,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药 发布公告,本公司于2026年9月23日已就若干本公司股东持有的3892.17万股本公司内资股转换为本公司H股向中国证监会提交备案申请(申请),占本公司于本公告日期已发行股本总额约6.75%。根据本公司章程及适用中国法律,本公司毋须召开股东大会以批准H股全流通以及转换及上市。本公司将根据上市规则的要求适时就H股全流通以及转换及上市的进展作出进一步公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144187504","title":"东阳光药:李文佳增持,好仓比例升至0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144187504","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144187504?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:32","pubTimestamp":1789551165,"startTime":"0","endTime":"0","summary":"李文佳于2026年5月21日增持广东东阳光药业股份有限公司(东阳光药)85.09万股H股股份,该股份根据雇员激励计划授予,同时公司完成了H股全流通。此次增持并非在联交所公开市场直接买卖,而是通过雇员激励计划获得。李文佳此次增持前持有东阳光药好仓0股,占比0.0%;增持后持股量为85.09万股,好仓比例升至0.27%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100852894","title":"东阳光药:蒋均才增持,好仓比例升至0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100852894","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100852894?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:22","pubTimestamp":1789550568,"startTime":"0","endTime":"0","summary":"蒋均才于2026年6月18日因就任东阳光药(06887)董事而申报权益,取得好仓21.55万股。该次权益变动系因成为董事而申报,并非在联交所公开市场直接买卖。蒋均才此次增持前持有东阳光药好仓0股,占比0.00%;增持后持股量为21.55万股,好仓比例升至0.07%。Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117579240","title":"东阳光药更新2026年8月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117579240","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117579240?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:22","pubTimestamp":1788427330,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年9月3日发布截至2026年8月31日止的股份变动月报表,报告期内公司股本情况未发生增加或减少,股本结构保持稳定。两类股份本月均无增减变动,月底合计注册股本仍为人民币576,656,047元。公告显示,当月无新增发行、回购、注销或其它股份变动活动。截至报告期末,东阳光药已符合适用的最低公众持股量要求。公司表示,将继续遵守香港联合交易所有限公司的相关上市规则和法律法规。本次月报由董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118789532","title":"东阳光药(06887)补充披露合伙基金主要条款及土地估值细节","url":"https://stock-news.laohu8.com/highlight/detail?id=1118789532","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118789532?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:36","pubTimestamp":1788187001,"startTime":"0","endTime":"0","summary":"2026年8月31日,东阳光药发布补充公告,就6月26日公布的关联交易进一步披露设立合伙企业基金及收购土地使用权的相关信息。③ 如仍有剩余利润,20%计入普通合伙人绩效报酬,80%按出资比例分配。普通合伙人管理费:基金首个五年,每年按实缴出资总额0.5%计取;第二个五年,每年按已投资但未退出本金余额0.5%计取。除上述补充披露外,原公告其他内容保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076609","title":"东阳光药发布2026年中期业绩:新旧动能切换,创新引擎接棒","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076609","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663076609?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:10","pubTimestamp":1788167406,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182581873","title":"东阳光药2026年中期营收10.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182581873","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182581873?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:08","pubTimestamp":1788167304,"startTime":"0","endTime":"0","summary":"东阳光药发布截至二零二六年六月三十日止六个月财报,期内营收为10.75亿元,同比下降44.50%。毛利为5.78亿元,同比减少60.60%,毛利率约为53.78%,较上年同期的75.70%减少21.92个百分点。同期税息、折旧及摊销前亏损达到2.27亿元,而上年同期为盈利4.30亿元。公司核心业务主要分为抗感染、慢病治疗及其他产品三大板块,其中抗感染药物实现销售收入约5.82亿元,慢病治疗类产品实现销售收入约4.64亿元,其他产品销售收入约0.29亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药2026年中期营收10.75亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663907654","title":"东阳光药(06887)发布中期业绩,收入10.75亿元 计划将强劲的营运现金流投入研发活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2663907654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663907654?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:08","pubTimestamp":1788167301,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药 发布截至2026年6月30日止6个月中期业绩,该集团取得收入10.75亿元,毛利5.78亿元,公司权益股东应占亏损6.04亿元,每股亏损1.09元。公司计划将强劲的营运现金流投入研发活动,以大幅提升资金使用效率,为研发管线提供充足的支持。此外,公司将就此前的关连交易安排进行优化调整,提升决策及资金配置效率,降低治理成本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK4585","BK4588","159399","SPHQ","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199543965","title":"东阳光药(06887)发布盈利警告:预计2026年上半年亏损约5.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199543965","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199543965?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:55","pubTimestamp":1787583352,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司8月24日公告,根据集团目前可得的未经审核管理账目及管理层初步估算,截至2026年6月30日的六个月,公司预期录得归属公司权益持有人的亏损及全面收益总额约人民币5.9亿元。与2025年同期亏损及全面收益总额约人民币0.5亿元相比,亏损规模增加约人民币5.4亿元。东阳光药仍在编制截至2026年6月30日止六个月的中期业绩,相关中期业绩公告预计将于2026年8月31日刊发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141461329","title":"东阳光药预计上半年亏损 主要因流感疫情缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1141461329","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141461329?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:52","pubTimestamp":1787583160,"startTime":"0","endTime":"0","summary":"东阳光药日前发布公告,预计公司上半年将出现亏损。这一预期亏损主要归因于流感疫情在上半年有所缓和。\n随着流感病例数量的减少,公司相关产品的市场需求也随之下降,进而影响了整体的销售业绩和财务状况。在疫情缓解的大背景下,公司面临了较大的经营压力。\n分析人士指出,流感季节性的波动是影响公司业绩的关键因素之一。随着公共卫生状况的改善,抗病毒药物的需求自然回落,这直接反映在了公司的预期业绩上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0442},{"period":"1month","weight":0.096},{"period":"3month","weight":0.1138},{"period":"6month","weight":-0.0655},{"period":"1year","weight":-0.1585},{"period":"ytd","weight":-0.0987}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0505},{"period":"3month","weight":0.0042},{"period":"6month","weight":-0.0681},{"period":"1year","weight":-0.1049},{"period":"ytd","weight":-0.0585}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药,亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威(磷酸奥司他韦),用于治疗流行性感冒(特别是甲型及乙型流行性感冒病毒),东卫恩(磷酸依米他韦),用于治疗丙型肝炎,及主要用于治疗敏感细菌引起的感染的仿制药,即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病,包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}